Author/Editor     Koren, S; Fleischmann, WR Jr
Title     Orally administered interferons suppress bone marrow function (43646)
Type     članek
Source     Proc Soc Exp Biol Med
Vol. and No.     Letnik 204, št. 2
Publication year     1993
Volume     str. 155-64
Language     eng
Abstract     The accepted routes of interferon (IFN) administration in clinical applications are intramuscular, subcutaneous, intraperitoneal, intratumor, and intravenous. Recently, oral administration of interferons has been shown to cause a suppression of peripheral white blood cell (WBC) counts. Moreover, orally administered interferons mediate their peripheral WBC suppression via a different mechanism than that of intraperitoneally administered interterons. This study extends the previous studies to show that the peripheral WBC suppression induced by oral interferon treatment reflects an actual bone marrow suppression. The bone marrow-suppressive effects of orally and subcutaneously administered recombinant human IFN-alphaA/D (rHu IFN-alphaA/D) have been partially characterized in kinetics studies and compared with the peripheral WBC-suppressive effects of orally and subcutaneously administered rHuIFN-alphaA/D. Oral and subcutaneous administrations of rHuIFN-alphaA/D cause a significant suppression of peripheral WBC counts with 1 day of rHuIFN-alphaA/D administration. This suppression reaches its maximum level with 3 days of rHuIFN-alphaA/D administration and plateaus over a 12-day treatment time. Similarly, oral and subcutaneous administrations of rHuIFN-alphaA/D cause a significant suppression of bone marrow function with 1 day of rHuIFN-alphaA/D administration. This suppression reaches its maximum level with 3 days of rHuIFN-alphaA/D administration and plateaus over a 12-day treatment time. Thus, the WBC-suppressive and bone marrow-suppressive effects of rHuIFN-alphaA/D administred either orally or subcutaneously parallel each other. The peripheral WBC-suppressive activities of orally and subcutaneously administered rHuIFN-alphaA/D diminish at the same rate, after cessation of rHuIFN-alphaA/D treatment. Peripheral WBC suppression is lost by 5 days affer cessation of rHuIFN-alphaA/D treatment.(trunc.)
Descriptors     INTERFERON-ALPHA
BONE MARROW
HEMATOPOIESIS
INTERFERON-BETA
MICE
MICE, INBRED C57BL
ADMINISTRATION, ORAL
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
INJECTIONS, SUBCUTANEOUS